135 related articles for article (PubMed ID: 38626662)
1. Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis.
Dodd KC; Ahmed R; Ambrose P; Holt JK; Jacob S; Leite MI; Miller JA; San PP; Spillane J; Viegas S; Sussman J
Neuromuscul Disord; 2024 May; 38():51-57. PubMed ID: 38626662
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.
Narayanaswami P; Sanders DB; Thomas L; Thibault D; Blevins J; Desai R; Krueger A; Bibeau K; Liu B; Guptill JT;
Lancet Neurol; 2024 Mar; 23(3):267-276. PubMed ID: 38365379
[TBL] [Abstract][Full Text] [Related]
3. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation.
Galor A; Jabs DA; Leder HA; Kedhar SR; Dunn JP; Peters GB; Thorne JE
Ophthalmology; 2008 Oct; 115(10):1826-32. PubMed ID: 18579209
[TBL] [Abstract][Full Text] [Related]
4. Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults.
Edwards Mayhew RG; Li T; McCann P; Leslie L; Strong Caldwell A; Palestine AG
Cochrane Database Syst Rev; 2022 Oct; 10(10):CD014831. PubMed ID: 36315029
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.
Meriggioli MN; Ciafaloni E; Al-Hayk KA; Rowin J; Tucker-Lipscomb B; Massey JM; Sanders DB
Neurology; 2003 Nov; 61(10):1438-40. PubMed ID: 14638974
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate in generalized myasthenia gravis: a systematic review.
Prado MB; Adiao KJB
Acta Neurol Belg; 2023 Oct; 123(5):1679-1691. PubMed ID: 36967437
[TBL] [Abstract][Full Text] [Related]
7. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis.
Heckmann JM; Rawoot A; Bateman K; Renison R; Badri M
BMC Neurol; 2011 Aug; 11():97. PubMed ID: 21819556
[TBL] [Abstract][Full Text] [Related]
8. Medical treatment options for ocular myasthenia gravis.
Antonio-Santos AA; Eggenberger ER
Curr Opin Ophthalmol; 2008 Nov; 19(6):468-78. PubMed ID: 18854691
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil as second line immunosuppressant in Myasthenia gravis--a long-term prospective open-label study.
Hanisch F; Wendt M; Zierz S
Eur J Med Res; 2009 Aug; 14(8):364-6. PubMed ID: 19666397
[TBL] [Abstract][Full Text] [Related]
10. Maintenance immunosuppression in myasthenia gravis, an update.
Morren J; Li Y
J Neurol Sci; 2020 Mar; 410():116648. PubMed ID: 31901719
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate as a Steroid-Sparing Agent in Myasthenia Gravis: A Preliminary Retrospective Study.
Rodolico C; Bonanno C; Brizzi T; Nicocia G; Trimarchi G; Lupica A; Pugliese A; Musumeci O; Toscano A
J Clin Neuromuscul Dis; 2021 Dec; 23(2):61-65. PubMed ID: 34808648
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil in myasthenia gravis: the unanswered question.
Phan C; Sanders DB; Siddiqi ZA
Expert Opin Pharmacother; 2008 Oct; 9(14):2545-51. PubMed ID: 18778192
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil in the therapy of severe myasthenia gravis.
Schneider C; Gold R; Reiners K; Toyka KV
Eur Neurol; 2001; 46(2):79-82. PubMed ID: 11528156
[TBL] [Abstract][Full Text] [Related]
14. Cancer occurrence following azathioprine treatment in myasthenia gravis patients: A systematic review and meta-analysis.
Zhang Z; Wang M; Xu L; Jiang B; Jin T; Shi T; Xu B
J Clin Neurosci; 2021 Jun; 88():70-74. PubMed ID: 33992207
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
Pasnoor M; He J; Herbelin L; Burns TM; Nations S; Bril V; Wang AK; Elsheikh BH; Kissel JT; Saperstein D; Shaibani JA; Jackson C; Swenson A; Howard JF; Goyal N; David W; Wicklund M; Pulley M; Becker M; Mozaffar T; Benatar M; Pazcuzzi R; Simpson E; Rosenfeld J; Dimachkie MM; Statland JM; Barohn RJ;
Neurology; 2016 Jul; 87(1):57-64. PubMed ID: 27306628
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis.
Bromberg MB; Wald JJ; Forshew DA; Feldman EL; Albers JW
J Neurol Sci; 1997 Sep; 150(1):59-62. PubMed ID: 9260858
[TBL] [Abstract][Full Text] [Related]
17. Treatment of myasthenia gravis with mycophenolate mofetil: a case report.
Meriggioli MN; Rowin J
Muscle Nerve; 2000 Aug; 23(8):1287-9. PubMed ID: 10918271
[TBL] [Abstract][Full Text] [Related]
18. Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial.
Rathinam SR; Gonzales JA; Thundikandy R; Kanakath A; Murugan SB; Vedhanayaki R; Lim LL; Suhler EB; Al-Dhibi HA; Doan T; Keenan JD; Rao MM; Ebert CD; Nguyen HH; Kim E; Porco TC; Acharya NR;
JAMA; 2019 Sep; 322(10):936-945. PubMed ID: 31503307
[TBL] [Abstract][Full Text] [Related]
19. The treatment of severe myasthenia gravis with immunosuppressive agents.
Mertens HG; Balzereit F; Leipert M
Eur Neurol; 1969; 2(6):321-39. PubMed ID: 4185500
[No Abstract] [Full Text] [Related]
20. Immunotherapy choice and maintenance for generalized myasthenia gravis in China.
Zhang C; Bu B; Yang H; Wang L; Liu W; Duan RS; Zhang M; Zeng P; Du C; Yang L; Shi FD
CNS Neurosci Ther; 2020 Dec; 26(12):1241-1254. PubMed ID: 33103369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
